GPR17 Inhibitors
GPR17 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of GPR17, a G-protein-coupled receptor (GPCR) involved in regulating various cellular responses, particularly in the context of inflammation, cellular damage, and tissue repair. GPR17 belongs to a subgroup of GPCRs that respond to extracellular signals, such as nucleotides and cysteinyl leukotrienes, playing an essential role in modulating downstream signaling pathways that control cellular responses to external stimuli. Inhibition of GPR17 disrupts its signaling capabilities, thereby affecting processes such as cell migration, proliferation, and the regulation of inflammatory responses. By targeting this receptor, researchers can investigate its role in coordinating complex signaling events across various cellular contexts.
The mechanisms by which GPR17 inhibitors work often involve blocking the receptor's ligand-binding site, preventing the binding of its natural ligands like nucleotides or leukotrienes. This inhibition results in the disruption of the downstream signaling cascade that GPR17 mediates, which often involves second messenger systems such as cyclic AMP (cAMP) or calcium ions. Some inhibitors may interfere with the receptor's ability to couple with G-proteins, hindering signal transduction. Researchers use GPR17 inhibitors to study the role of GPCR signaling in processes such as tissue repair, cellular communication, and the regulation of inflammatory pathways. By inhibiting GPR17, scientists can gain insights into how GPCR-mediated signaling influences cellular behavior and how these pathways are intricately involved in maintaining homeostasis and responding to environmental changes. These inhibitors serve as valuable tools for dissecting the molecular mechanisms of GPCR signaling and its impact on cellular function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bexarotene | 153559-49-0 | sc-217753 sc-217753A | 10 mg 100 mg | $55.00 $250.00 | 6 | |
Bexarotene, a synthetic retinoid, may downregulate GPR17 expression by binding to retinoid X receptors, which can initiate transcriptional repression sequences that silence the GPR17 gene or hinder its promoter activity. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Fenofibrate could reduce GPR17 expression by activating PPARα, leading to upregulation of genes that encode repressors of GPR17 transcription. This may result in a decrease in GPR17 mRNA synthesis and, consequently, protein levels. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
Through PPARγ agonism, rosiglitazone may decrease GPR17 expression by triggering transcriptional cascades that elevate the production of proteins that can bind to the GPR17 promoter region and repress its transcriptional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, as a PI3K inhibitor, may decrease GPR17 expression by preventing the activation of Akt, which can control the translation of GPR17 through mTOR signaling or by altering the stability of GPR17 mRNA. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB203580 could suppress GPR17 expression by inhibiting p38 MAPK, an enzyme that may phosphorylate and activate transcription factors or coactivators involved in the transcription of the GPR17 gene. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 has the potential to decrease GPR17 expression by inhibiting JNK activity, which could be responsible for initiating transcription factors or histone modifications that enhance GPR17 gene expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 may inhibit GPR17 expression by targeting and inhibiting MEK, which in turn, could prevent the activation of transcription factors that bind to the promoter region of the GPR17 gene, thereby reducing its transcription. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin could downregulate GPR17 expression by inhibiting mTOR, a kinase that facilitates cap-dependent translation, including the translation of proteins that are crucial for GPR17 mRNA transcription and stability. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $90.00 $317.00 | 17 | |
Chelerythrine might decrease GPR17 expression by inhibiting protein kinase C (PKC), which could be involved in the phosphorylation of transcription factors necessary for GPR17 gene transcription or in the post-transcriptional modification of GPR17 mRNA. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin may downregulate GPR17 expression by inhibiting PI3K, leading to a reduction in Akt phosphorylation. This reduction could result in a decrease in transcription factor activity or mRNA stability that is necessary for maintaining GPR17 expression levels. | ||||||